Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256867
Status:
COMPLETED
Last Update Posted:
2018-07-02
First Post:
2005-11-18
Brief Title:
A Study In Patients With Type 2 Diabetes Mellitus
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 16 Week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication GSK523338 to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the effect of medicines for type 2 diabetes and lipids control This study will require about 6 office visits for lab tests and examinations All study related medicines and medical examinations will be provided at no cost to the subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None